Table 1.
Ref. | n | BT-dose U | Initial symptomatic response | Injection rate | Long-term symptomatic response | Follow up (mo) |
Wehrmann et al[19] | 20 | 100 | 80% | 2.5 | 70% | 24 |
Annese et al[20] | 36 | 100 | 90% | 0 | 78% | 6 |
Pasricha et al[28] | 31 | 80 | 90% | 1.6 | 68% | 12 |
Fishman et al[31] | 60 | 80 | 70% | 1.3 | 36% | 12 |
Annese et al[32] | 38 | 100 | 82% | 1 | 68% | 24 |
Gordon et al[100] | 16 | 80 | 75% | 1.25 | 58% | 7 |
Cuillière et al[101] | 55 | 80 | 85% | 1.2 | 60% | 6 |
Vaezi et al[102] | 22 | 100 | 64% | 1.1 | 32% | 12 |
BT: Botulinum toxin.